A ‘renaissance’ for Mylan...well, part of Renaissance, anyway

Mylan pays $950 million for Renaissance’s specialty and generics business focused on topicals

Register for free to listen to this article
Listen with Speechify
HERTFORDSHIRE, U.K. & PITTSBURGH—Mylan N.V. on May 13 announced an agreement to acquire the non-sterile, topicals-focused specialty and generics business of Renaissance Acquisition Holdings LLC for $950 million in cash at closing, plus additional contingent payments of as much as $50 million, subject to customary adjustments. Mylan expects the transaction to be immediately accretive to its adjusted diluted earnings per share upon closing.
What this brings to Mylan is what it calls a “complementary portfolio” of more than two dozen branded and generic topical products, an active pipeline of another couple dozen products, and an established U.S. sales and marketing infrastructure targeting dermatologists.
“The dermatology/topicals space has long been an area of focus for Mylan and one that we have targeted for expansion. This is a strong and growing business in a very attractive category, which is highly complementary to Mylan’s existing assets and the pending addition of the Meda dermatology portfolio,” says Mylan CEO Heather Bresch. “We see significant opportunities to accelerate the growth potential of the business as part of the global Mylan platform, as we maximize our combined assets across customer channels and geographies. This acquisition was accounted for in our anticipated capital structure and does not require any additional financing. As such, we see no impact to the leverage ratio of 3.8x debt-to-adjusted EBITDA we anticipated following the closing of the Meda transaction, and we will retain ample financial flexibility for future value-creating initiatives.”
Regarding Meda, Mylan made a multibillion-dollar acquisition deal with the company early this year (see “Mylan makes $9.9B offer for Meda” story here). About 60 percent of Meda’s product sales are in the prescription area and around 40 percent are non-prescription cosmetic and/or over-the-counter products. Meda has a broad product portfolio but a trio of areas—respiratory, dermatology and pain and inflammation—make up about half of company sales. Meda does not conduct early-stage pharmaceutical development; rather, new products have been secured through acquisitions.
Getting back to Renaissance, Mylan says it also gains an integrated manufacturing and development platform and “a leading topicals-focused contract development and manufacturing organization.”
Renaissance, privately controlled and majority-owned by RoundTable Healthcare Partners, will retain its sterile-focused businesses and associated manufacturing facility.
“With the addition of the Business’s broad and durable portfolio, exciting pipeline of topical products, and strong manufacturing and R&D capabilities, we will have critical mass in the dermatology/topicals area and catapult to a leading position in this space,” said Mylan President Rajiv Malik. “We see significant opportunities to maximize our combined dermatology/topicals business and integrated operating platform on a worldwide basis, and expect it to be yet another key global franchise for us, even further strengthening and diversifying our business. We look forward to welcoming the business’s talented employees to Mylan upon closing and working together to maximize the potential of our combined organization to set new standards in healthcare in this area. We also look forward to continuing to provide the business’s valued customers with the high quality service they are accustomed to.”
The Renaissance business had approximately $370 million in 2015 revenues and employs approximately 1,200 people. The business’s commercial segment has what Mylan call “a diversified and attractive portfolio of specialty brands and generic products in the dermatology space, as well as a deep pipeline of complex topical generics and brands in active development.”
The business’ manufacturing sites have capabilities and capacity in creams, ointments, aerosols/foams, gels, suspensions, liquids and suppositories that are said to be complementary to Mylan’s existing capabilities.

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue